|
ENDURANCE-4
|
Asselah, 2018 [36]
|
Glecaprevir/pibrentasvir
|
NA
|
AbbVie Deutschland GmbH & Co. KG
|
Non-controlled cohort study
|
24
|
1
|
121
|
36.4
|
52.66 (11)
|
|
M41008−1002,
|
Mrowietz, 2017 [37]
|
Dimethyl fumarate
|
Placebo/dimethyl fumarate + ethyl hydrogen fumarate
|
Almirall, S.A.
|
Superiority and non-inferiority (head to head)
|
16
|
3
|
699
|
35.3
|
44.2 (14.5)
|
|
ERC 231
|
Archer, 2015 [38]
|
Dehydroepiandrosterone (DHEA)
|
Placebo
|
Endoceutics
|
Superiority (head to head)
|
12
|
3
|
255
|
100
|
58.5 (6)
|
|
Clarity
|
Giovannoni, 2010 [39]
|
Cladribine
|
Placebo
|
Merck Serono International S.A.
|
Superiority (head to head)
|
96
|
3
|
1326
|
67.6
|
38.6 (10)
|
|
NN7088-3885
|
Trakymiene, 2020 [40]
|
Turoctocog Alfa pegol
|
NA
|
Novo Nordisk A/S
|
Non-controlled cohort study
|
26
|
1
|
68
|
0
|
6 (3.3)
|
|
SUSTAIN 2
|
Ahren, 2017 [41]
|
Semaglutide
|
Sitagliptine
|
Novo Nordisk A/S
|
Superiority and non-inferiority (head to head)
|
56
|
4
|
1231
|
49.4
|
55.1 (10)
|
|
SUSTAIN 5
|
Rodbard, 2018 [42]
|
Semaglutide
|
Placebo
|
Novo Nordisk A/S
|
Superiority (head to head)
|
30
|
4
|
397
|
43.9
|
58.8 (10.1)
|
|
TRANSFORM-1
|
Fedgchin, 2019 [43]
|
Esketamine
|
Placebo
|
Janssen-Cilag International NV
|
Superiority (head to head)
|
4
|
3
|
346
|
70.3
|
46.3 (11.6)
|
|
SUSTAIN-1
|
Daly, 2019 [45]
|
Esketamine
|
Placebo
|
Janssen-Cilag International NV
|
Superiority (head to head)
|
16
|
2
|
705
|
64.8
|
46.1 (11.1)
|
|
SUSTAIN-2
|
Wajs, 2020 [44]
|
Esketamine
|
NA
|
Janssen-Cilag International NV
|
Non-controlled cohort study
|
52
|
1
|
802
|
62.6
|
52.2 (13.7)
|
